Welcome to our dedicated page for Blueprint Medicines SEC filings (Ticker: BPMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the science-heavy language in Blueprint Medicines鈥� SEC documents can feel like decoding a genomic sequence. Pipeline updates on selective kinase therapies, milestone payments from collaborations, and cash-runway disclosures are scattered across hundreds of pages. If finding that information in a 10-K or spotting insider buys before an FDA catalyst seems daunting, you鈥檙e not alone.
Stock Titan solves the problem. Our platform delivers AI-powered summaries that translate complex biotech terminology into plain English, then links you straight to the source form. Need the Blueprint Medicines quarterly earnings report 10-Q filing? One click. Curious about Blueprint Medicines insider trading Form 4 transactions or real-time alerts for Blueprint Medicines Form 4 insider transactions real-time? We surface them instantly. From a Blueprint Medicines annual report 10-K simplified to a Blueprint Medicines 8-K material events explained, our AI highlights what moves the stock.
Here鈥檚 what you can do on this page:
- Review every 10-K, 10-Q and 8-K with side-by-side Blueprint Medicines earnings report filing analysis
- Track Blueprint Medicines executive stock transactions Form 4 and monitor patterns before clinical readouts
- Dive into the Blueprint Medicines proxy statement executive compensation to see how management is rewarded for pipeline milestones
- Use our natural-language search鈥斺��understanding Blueprint Medicines SEC documents with AI鈥� returns plain-spoken answers, not PDFs
Every filing posts within minutes of hitting EDGAR, and our expert layer explains valuation drivers like clinical trial spend, collaboration revenue and patent updates. Complex biotech filings, now clear and actionable.
Blueprint Medicines Corp. (NASDAQ: BPMC) filed Amendment No. 1 to its Schedule 14D-9, updating shareholders on Sanofi鈥檚 $129.00-per-share cash tender offer plus a non-transferable contingent value right (CVR) worth up to an additional $6.00 per share. The amendment provides supplemental disclosure on (i) financial advisor valuation work and (ii) regulatory and legal developments.
Financial advisor analyses. Centerview鈥檚 discounted cash-flow (DCF) generated an implied equity value range of $115.80-$148.50 per share, while Jefferies鈥� DCF showed $112.50-$143.65. Both were benchmarked against the implied consideration of approximately $131.00 (cash + CVR midpoint). Centerview鈥檚 precedent-premium study implied $136.80-$187.50 per share. Historical trading over the prior 52 weeks ranged $79.22-$120.50; 21 sell-side price targets ranged $83-$167 (median $130).
Regulatory clearances achieved. The U.S. HSR waiting period expired on 9 July 2025, satisfying a key closing condition. Clearance milestones were also reached in Austria (8 July 2025), Germany (30 June 2025) and Italy (25 June 2025, Golden Power exemption). These approvals materially reduce antitrust risk for the transaction.
Legal proceedings. Two shareholder suits (Williams and Phillips) filed in New York allege the Schedule 14D-9 is materially incomplete; 12 additional demand letters request further disclosure. The company denies wrongdoing but voluntarily provided the new disclosures to mitigate delay or expense.
Bottom line. The amendment does not change economic terms, but confirms multiple regulatory approvals and reveals valuation ranges that largely bracket the $131 offer, supporting fairness. Litigation represents a manageable but ongoing risk.
Blueprint Medicines Corporation (BPMC) director Jeffrey W. Albers received a significant equity grant on June 18, 2025. The transaction involved 3,902 restricted stock units (RSUs) awarded at a price of $128.12 per share.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents one share of common stock
- Following the transaction, Albers directly owns 150,532 shares
This Form 4 filing, signed by attorney-in-fact Melissa Masse on June 23, 2025, reflects standard director compensation practices and demonstrates continued alignment between board members and shareholder interests through equity-based compensation.
Blueprint Medicines Corp (BPMC) Director Mark Alan Goldberg received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, valued at $128.12 per share. Following this transaction, Goldberg directly owns 22,156 shares of common stock.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents the right to receive one share of common stock
- Total value of granted RSUs: approximately $500,000
This Form 4 filing, executed by attorney-in-fact Melissa Masse on June 23, 2025, represents standard equity compensation for a board member, aligning director interests with shareholders through stock ownership.
Blueprint Medicines Corp (BPMC) director Lynn Seely received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, with a value of $128.12 per unit. Following this transaction, Seely's direct ownership increased to 17,156 shares.
Key terms of the RSU grant:
- 100% vesting occurs at the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents a contingent right to receive one share of common stock
- Total grant value: approximately $500,000
This Form 4 filing, submitted by attorney-in-fact Melissa Masse on June 23, 2025, reflects standard director compensation practices through equity grants. The transaction was reported within the required SEC filing deadline of two business days.
Blueprint Medicines Director Daniella Beckman received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, with a value of $128.12 per unit, bringing her total direct holdings to 14,744 shares.
The RSUs have specific vesting terms: they will vest 100% on either June 18, 2026 or the next annual stockholder meeting, whichever occurs first. Each RSU represents the right to receive one share of common stock upon vesting.
This Form 4 filing, submitted by Attorney-in-Fact Melissa Masse on June 23, 2025, reflects standard equity compensation for a board member, indicating continued alignment between director and shareholder interests. The transaction was executed under regular compensation arrangements rather than through a Rule 10b5-1 trading plan.
Blueprint Medicines Corp (BPMC) director Alexis Borisy received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, at a price of $128.12 per share. Following this transaction, Borisy directly owns 78,062 shares of the company.
Key details of the RSU grant:
- Vesting occurs at 100% of underlying shares on the earlier of: - June 18, 2026 - Next annual stockholders' meeting
- Each RSU represents a contingent right to receive one share of common stock
- Transaction was reported via Form 4 filing on June 23, 2025
This equity grant appears to be part of the company's director compensation program, aligning the director's interests with those of shareholders through stock ownership.
Blueprint Medicines Director Habib J. Dable received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, at a reference price of $128.12 per share. Following this transaction, Dable directly owns 12,644 shares of the company.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents the right to receive one share of common stock upon vesting
- The transaction was reported via Form 4 filing, indicating changes in beneficial ownership
This equity grant appears to be part of the company's director compensation program, aligning the director's interests with those of shareholders through stock ownership. The filing was signed by Melissa Masse as attorney-in-fact on June 23, 2025.
FAQ
What is the current stock price of Blueprint Medicines (BPMC)?
What is the market cap of Blueprint Medicines (BPMC)?
